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30, 2008 within a large nationwide network of outpatient oncology clinics were 
studied using US Oncology’s iKnowMed EMR. Costs included only those incurred 
within the network of outpatient oncology clinics and were derived using Medicare 
reimbursement rates. Patients were matched across regimens on key confounding 
factors at initiation of treatment: age, stage at diagnosis, ECOG performance status, 
and comorbidity index. A variable N:M matching ratio was used. Patients were fol-
lowed through June 30, 2009. A 95% conﬁdence intervals were estimated by boot-
strapping (2500 samples) the within-cell differences in cost and time to progression 
(TTP) of matched patients. RESULTS: A total of 1194 patients were identiﬁed: 48 
received P/P, 279 received C/P + B, and 867 received C/P. We found that P/P exhibited 
dominance vs. C/P + B, with higher effectiveness (mean difference in TTP = 1.7 
months; CI = 1.1- 2.3 months) and lower cost (mean cost difference = −$22,890; CI 
= $−25,445–$−20,335). Compared to C/P, P/P had higher effectiveness (mean differ-
ence in TTP = 2.0 months; CI = 1.7- 2.4 months) but also higher costs (mean cost 
difference = $12,603; CI = $11,579–$13,667) with an incremental cost effectiveness 
of $6,335/progression-free month (CI = 5,432–7,404). CONCLUSIONS: This study 
suggests that P/P may be a cost-effective 1st line NSCLC treatment in the outpatient 
community setting. Costs differences were substantial by regimen while differences in 
TTP were relatively small from a clinical perspective. While this preliminary study 
utilized conservative analytic methods and controlled for several key confounding 
factors, future large studies should attempt to further address selection bias and 
residual confounding.
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HEALTH CARE COSTS OF METASTATIC SQUAMOUS CELL 
CARCINOMA OF HEAD AND NECK—FINDINGS FROM LINKED 
SEER-MEDICARE DATA
Parthan A1, Kulakodlu M2, Deﬂin M1, Taylor D3, Barber B4, Zhao Z4
1i3 Innovus, San Francisco, CA, USA, 2i3 Innovus, Eden Prairie, MN, USA, 3i3 Innovus, 
Medford, MA, USA, 4Amgen, Inc, Thousand Oaks, CA, USA
OBJECTIVES: To estimate health care utilization and costs for patients with incident 
metastatic squamous cell carcinoma of head and neck (mSCCHN). METHODS: 
Incident mSCCHN patients between 1993 and 2005 were identiﬁed in the SEER-
Medicare database using ICD-O codes for primary site and histology with a “distant” 
tumor in the SEER staging variable. Individuals 65 years or older at the time of 
diagnosis, with at least 12 months of data preceding initial diagnosis were included. 
The index date was deﬁned as the date of diagnosis; subjects were followed from 30 
days prior to the index date until death or the end of Medicare claims data (December 
31, 2007), whichever occurred ﬁrst. Chemotherapy use was identiﬁed using HCPCS 
codes. Resource use and health care costs were estimated using the person-years 
approach to account for patients having different lengths of follow-up. RESULTS: A 
total of 1420 subjects with mSCCHN were included in this analysis. Mean age was 
74 (SD 6.7) years and 70% were males. Mean Charlson comorbidity score without 
malignancy was 1.4 (SD 1.6) and mean duration of follow-up was 30 months (SD 
33). Forty-eight percent of patients received chemotherapy. Carboplatin (18%) was 
the most commonly used agent followed by paclitaxel (13%) and cisplatin (11%). 
The mean number of visits per patient per year was 9.7 (SD 10.7) for outpatient care 
and 2.9 (SD 3.7) for inpatient care. Average annual inpatient days per patient were 
31.4 days (SD 51.1). About 40% of the patients received hospice care. Mean total 
annual health care costs per patient were $155,307, cost of outpatient care constituted 
51% and inpatient care 34%. CONCLUSIONS: Inpatient and outpatient costs are 
the key drivers of total health care costs for patients with mSCCHN.
HE3
CAN INNOVATION BE REWARDED WITH THE APPLICATION OF RIGID 
COST-EFFECTIVENESS THRESHOLDS? THE HER2+VE BREAST CANCER 
CASE STUDY
Ray J, Cirrincione A
F. Hoffmann-La Roche Ltd., Basel, Switzerland
OBJECTIVES: Trastuzumab (Tras) in combination with chemotherapy is the current 
treatment standard in patients with early and metastatic breast cancer (BC) who are 
HER2 positive (HER2+). Any regimen under development will have to be compared 
to Tras both in pivotal clinical trials and during economic assessment. This study raises 
important policy questions by estimating the feasibility of demonstrating cost-effec-
tiveness (CE) against conventional UK NICE thresholds (£ 20–30,000/QALY gained) 
for new regimens developed in different lines of treatment for HER2+ BC and incen-
tives for development where rigid thresholds are applied. METHODS: Three CE 
models were developed using rates of disease progression, survival and efﬁcacy data 
from 3 Tras clinical trials: HERA for adjuvant, M77001 for 1st-line metastatic and 
GBG-26 for 2nd-line metastatic BC. Isometrics curves were generated for each model 
whereby each point on the curve corresponded to where the progression-free & overall 
survival hazard ratios and increase in total costs for the new treatment versus Tras 
was estimated to result in an ICER of £ 30’000/QALY. Costs and utility values were 
based on published literature from the UK-NHS perspective. RESULTS: Assuming a 
5-year duration of efﬁcacy in early BC (PFS hazard ratio of 0.75), the model estimated 
that a new treatment could be considered cost-effective with medication acquisition 
costs 81% above Tras. In the metastatic setting (1st and 2nd-line), similar incremental 
improvements in efﬁcacy, for the OS and PFS hazard ratios over 5 years, suggests that 
a new regimen could not have medication acquisition costs more than 6–7% above 
Tras. CONCLUSIONS: Given current treatment costs of the background regimen, it 
is unlikely that any new combination regimen will be cost-effective using UK thresh-
olds. Results were not sensitive to the magnitude of the incremental survival beneﬁt 
due to the high correlation between treatment beneﬁt, treatment duration (until cancer 
progression), and overall treatment costs.
HE4
CHARACTERIZATION OF FREQUENT HOSPITAL EMERGENCY 
DEPARTMENT (ED) USE BY UN- OR UNDERINSURED PERSONS
Khurshid A1, Strassels S2
1Integrated Care Collaboration, Austin, TX, USA, 2University of Texas at Austin, Austin, 
TX, USA
OBJECTIVES: ED use for non-emergencies contributes to crowding, increased health 
care costs, and, potentially, poor clinical outcomes. Efforts to decrease inappropriate 
ED use have focused on insured individuals. The purpose of this retrospective cohort 
study was to characterize frequent ED use among un- and underinsured individuals 
in central Texas. METHODS: Data were obtained from the ICare system, which 
includes information for > 800,000 individuals and > 5 million encounters within 24 
Central Texas health care providers who arrange for or provide care for uninsured or 
underinsured individuals. Persons who received care from an ICare-participating orga-
nization during calendar year 2007 were included in these analyses. Frequent ED use 
was deﬁned as at least 6 ED visits within either a calendar quarter or any contiguous 
three-month period. Linear regression was used to estimate the relation between 
patient characteristics and total ED visits among frequent users. RESULTS: There 
were 216,364 ED visits in 2007; 128,538 individuals had at least 1 ED visit and 0.7% 
(n = 892) were considered frequent ED users. Frequent users were mainly female 
(55.6%), and Caucasian (55.8%). Hispanics and African-Americans accounted for 
14.2% and 17.3% of frequent users, respectively. The regression model accounted for 
12.1% of variability in the outcome. Total clinic visits (beta = 0.05, p 0.037, 95% CI 
0.003–0.094), inpatient admissions (beta = 1.35, p < 0.001, 95% CI 0.976–1.716) 
and having any mental health diagnosis in any ED visit (beta = 3.278, p < 0.001. 95% 
CI 2.060–4.496) were positively and statistically signiﬁcantly associated with the 
number of ED visits among frequent users, after adjusting for age, sex, and race. 
CONCLUSIONS: In 2007, frequent users accounted for < 1% of ED users, and 5.4% 
of total ED use. A study of these frequent users may help identify opportunities for 
intervention to help underlying causes for these frequent visits.
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COMPARATIVE-EFFECTIVENESS VERSUS COST-EFFECTIVENESS: A 
COMPARISON OF THE FRENCH AND SCOTTISH APPROACHES TO 
SINGLE TECHNOLOGY ASSESSMENT (STA)
Bending MW1, Hutton J1, McGrath C2
1University of York, York, UK, 2Pﬁzer, Walton on the Hill, Surrey, UK
OBJECTIVES: To compare the pharmaceutical STA guidance advice of Haute Autorité 
de santé (HAS) which appraises clinical efﬁcacy/safety against the Scottish Medicines 
Consortium (SMC) in which appraisal includes both clinical and cost-effectiveness. 
METHODS: All English translated advice were downloaded from the HAS website 
resulting in 78 transparency committee opinions for between 2005 and 2009. These 
were matched with SMC advice, resulting in 39 matched drugs. A comparison between 
drug advice, the clinical evidence through identiﬁcation of trials on the CENTRAL 
database of the Cochrane library and a statistical analysis was performed on improve-
ment in medical beneﬁt (ASMR) supplied by HAS and the cost-utility estimates (CQG) 
of the SMC. RESULTS: The HAS and SMC had the same advice in 14/39 (36%) of the 
drug comparisons. The average number of trials included were 2 trials in HAS advice 
and 1.8 trials in SMC advice with more comprehensive detail on the efﬁcacy in HAS 
advice. Each matched comparison had at least one common trial and 30% of guidance 
included different additional trials. The correlation between the medical improvement 
provided by HAS and the SMC CQG were analysed and show that for those treatments 
considered cost saving by the SMC the ASMR was on average 4.6. The CQG for 
£0-£10,000 had an average ASMR; 3.6, £10,000-£20,000; 2.8, £20,000-£30,000; 3.1, 
and £30,000+; 3.4, showing little correlation between ASMR and CQG. CONCLU-
SIONS: The differences in guidance advice reﬂect the countries different HTA pro-
cesses, interpretation of clinical efﬁcacy and approaches to economics. HAS advice 
provided more detailed information on the clinical efﬁcacy in comparison to SMC for 
these drugs. The SMC presented formal analysis of cost-effectiveness in comparison to 
France where economic issues are considered by the economic committee and not 
reported. The transparency committee implicitly uses economics as the choice of ASMR 
inﬂuences pricing decisions and the cost-effectiveness of treatments.
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VARIABILITY IN UTILIZATION OF INNOVATIVE DRUGS IN EUROPE AS 
A RESULT OF HEALTH TECHNOLOGY ASSESSMENT AND FUNDING 
PROCEDURES: EXAMPLES OF TRASTUZUMAB AND CETUXIMAB
Toumi M1, Misset JL2, Cristeau O1, Krukowski L3, Aballea S4, Lamure M5
1University Claude Bernard Lyon 1, Lyon, France, 2Hopital Saint Louis, Paris, France, 
3Synovate, London, UK, 4CREATIV-CEUTICAL, Paris, France, 5University Claude Bernard 
Lyon 1, Paris, France
OBJECTIVES: Prices of recently launched monoclonal antibodies are high and their 
accessibility differs across Europe. Trastuzumab (TRZ) was recommended by payers 
for early and advanced breast cancer (BC) in Europe, with differences in the process 
and timelines of recommendations. Cetuximab (CTX) for metastatic colorectal cancer 
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(mCRC) was not recommended in the UK (until June 2009), but accepted under a 
price volume agreement scheme with prior authorization in Italy, and without restric-
tion in France and Germany. These products are funded on top of DRG costs in 
France, but not in other countries. We reviewed how such differences might affect 
usage of TRZ and CTX in France, Germany, Italy and UK. METHODS: Data on 
drug utilization from June 2006 to July 2009 were extracted from the Synovate Oncol-
ogy Monitor, an ongoing database tracking prescribing of anti-cancer therapies. 
Sample sizes varied between countries and indications, from 1700 to 6200 patients. 
RESULTS: Proportions of patients receiving TRZ from July 08 to June 09 ranged 
from 9% (UK) to 16% (Italy) in early BC, 12% (Italy) to 19% (France) in ﬁrst-line 
advanced BC and 10% (France) to 34% (Italy) in second-line (irrespective of HER2 
screening). For CTX, utilization rates ranged from 0% (UK) to 13% (France) in ﬁrst-
line and 2% (UK) to 19% (Italy) in second-line. Utilization of TRZ increased over 
time in early stage BC. Utilization of CTX was stable in France, increased in Germany 
and decreased in Italy. Dosages and patient proﬁles were comparable across countries. 
CONCLUSIONS: Funding on top of DRG does not appear to increase drug uptake. 
Health technology assessment conclusions inﬂuence utilization strongly. When access 
is granted, administrative constraints may reduce ﬁrst-line utilization to the beneﬁt of 
second-line. This should be considered when decisions are made about access to 
innovative medicine.
HT3
MULTICRITERIA DECISION ANALYSIS (MCDA) FOR DRUG COVERAGE 
DECISION BY A PUBLIC HEALTH PLAN: CASE STUDY OF TRAMADOL 
FOR CHRONIC NON-CANCER PAIN (CNCP) IN CANADA
Tony M1, Goetghebeur M1, Wagner M1, Khoury H1, Rindress D1, Oh P2
1BioMedCom Consultants Inc., Dorval, QC, Canada, 2University of Toronto, Toronto, 
ON, Canada
OBJECTIVES: To ﬁeld-test a decision support framework (EVIDEM) and explore its 
utility to a drug advisory committee using tramadol for chronic non-cancer pain 
(CNCP) as a case study. METHODS: The EVIDEM framework includes a multicri-
teria decision analyses matrix (MCDA) composed of 15 quantiﬁable components of 
decision including six domains (disease impact, context of intervention, intervention 
outcomes, type of beneﬁt, economics and quality of evidence) and a qualitative tool 
including six components of decision regarding ethical considerations, system capacity 
and political/historical context. A synthesized health technology assessment (HTA) 
report tailored to investigate each component of decision was developed for tramadol 
for CNCP. MCDA weights and scores, and qualitative considerations were provided 
by each committee member to evaluate tramadol from a public health plan perspective. 
RESULTS: The committee estimated the value of tramadol for CNCP at 44% (min: 
36%, max: 61%) of maximum value on the MCDA scale. Main contributors to the 
MCDA value estimate were size of population affected by disease (15% of total), 
disease severity (11%) and impact on adverse event expenditures (8%). Limited 
improvement in efﬁcacy, safety and patient reported outcomes were not signiﬁcant 
contributors to MCDA value. For a majority of committee members, ethical consid-
erations on utility, efﬁciency and fairness had respectively a positive, neutral and 
negative impact on the value of tramadol. CONCLUSIONS: By systematizing consid-
eration of all components of decision and underlying evidence, the framework allows 
consistent approach to evaluating health care interventions. Further testing and valida-
tion is needed to advance MCDA approaches in health care decisionmaking.
HT4
PRAGMATIC CLINICAL TRIALS FOR DRUG APPROVAL: IS IT REALISTIC?
Mohr P1, Sonnad S2, Mullins CD3, Whicher D1, Goldsack J2, Tunis SR1
1Center for Medical Technology Policy, Baltimore, MD, USA, 2University of Pennsylvania, 
Philadelphia, PA, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA
BACKGROUND: Patients, clinicians, payers and policymakers increasingly are inter-
ested in understanding comparative “real world” effectiveness of pharmaceutical 
products, often noting that traditional clinical trials performed for regulatory approval 
may not address important questions about the full range of beneﬁts and harms of 
new drugs used in typical clinical settings. While more pragmatic designs are used for 
post-marketing studies, to date, no group formally has considered their utility and 
feasibility for regulatory approval trials. METHODS: In 2009, the Center for Medical 
Technology Policy convened an expert stakeholder working group to characterize 
recurring gaps in evidence that generally are not addressed in regulatory trials, explore 
the reasons for those shortcomings, and generate ideas for improving methods to make 
these trials more informative for patient and physician choices and reimbursement and 
coverage decisions. The working group included representatives from pharmaceutical 
companies, regulatory bodies, private and public payers, academics, consumers, and 
technology assessment organizations. Using discussions from this meeting and contin-
ued engagement of the working group over time, we developed a conceptual, meth-
odological and policy framework to improve the design and implementation of 
pragmatic regulatory trials. RESULTS: There emerged greater than anticipated con-
sensus among the regulators and payers participating in the working group that some 
pragmatic features are desirable and feasible to include in regulatory trials. The 
working group developed eight basic principles for making regulatory trials more 
pragmatic, covering the engagement of post-regulatory decision makers early in the 
design process to methods for designing more efﬁcient trials. CONCLUSIONS: The 
optimal approach to pragmatic trials may not involve incorporating all possible 
pragmatic features, as are typically associated with large, simple trials. Some domains 
of pragmatism are more important to payers than others and any incremental move-
ment toward more pragmatic designs may be not only highly valuable, but feasible.
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INCORPORATING TARIFF-LEVEL UNCERTAINTY AROUND ESTIMATES 
FROM THE CATALOGUE OF EQ-5D SCORES
Sullivan P1, Ghushchyan VH2, Slejko JF2
1Regis University School of Pharmacy, Denver, CO, USA, 2University of Colorado Denver, 
Aurora, CO, USA
OBJECTIVES: Analysts typically take as “ﬁxed” the underlying tariff scoring function 
of a given utility instrument when conducting probabilistic sensitivity analysis, ignor-
ing an important source of uncertainty. An “off-the-shelf” catalogue of EQ-5D scores 
from a nationally representative U.S. population has recently been published. The 
current study aims to incorporate the uncertainty in the underlying U.S. EQ-5D tariff 
function by estimating conﬁdence intervals around estimates from the catalogue. 
METHODS: The Medical Expenditure Panel Survey (MEPS), a general population 
survey in the U.S., was pooled (2000, 2001, 2002 and 2003) to create a sample of 
79,524 adults with valid EQ-5D responses. Chronic conditions were classiﬁed by 
ICD-9 codes and Clinical Classiﬁcation Category (CCC) codes. Censored least abso-
lute deviations (CLAD) regression methods were used to estimate the marginal disutil-
ity of each condition controlling for age, comorbidity, gender, race, ethnicity, income 
and education. US tariffs for the EQ-5D (Shaw) were applied to questionnaire 
responses. However, instead of taking the US EQ-5D tariff as a “ﬁxed” function of 
the questionnaire responses, 500 bootstraps were conducted drawing from a distribu-
tion of possible EQ-5D tariffs based on the standard errors from the original scoring 
estimation. RESULTS: A catalogue of marginal disutility (EQ-5D) scores for each 
chronic ICD-9 and CCC code were estimated 500 times based on the distribution of 
possible EQ-5D tariffs. The 95% range of these potential marginal disutilities is 
presented and compared. CONCLUSIONS: Scores and marginal disutilities for a wide 
variety of chronic ICD-9 and CCC codes can be used to estimate QALYs in cost-
effectiveness analyses. This research provides a range of values around each marginal 
disutility in the catalogue of “off-the-shelf” EQ-5D scores. Uncertainty in the underly-
ing US EQ-5D estimation tariff is incorporated in these ranges to encourage better 
understanding of the inherent uncertainty in EQ-5D estimates and to facilitate future 
probabilistic sensitivity analyses.
PR2
EVALUATING THE MEASUREMENT PROPERTIES OF AN AUGMENTED 
EQ-5D WITH THE INCLUSION OF TWO SINGLE QUALITY-OF-LIFE 
(QOL) INDICATORS USING THE MEDICAL EXPENDITURE PANEL 
SURVEY (MEPS)
Gu NY1, Bond TG2, Craig BM3
1Pharmerit North America, LLC, Bethesda, MD, USA, 2James Cook University, Townsville, 
QLD, Australia, 3Mofﬁtt Cancer Center, Tampa, FL, USA
OBJECTIVES: To evaluate the measurement properties of the EQ-5D proﬁle aug-
mented with its 0–100 mm visual analogue scale (VAS) and a 5-point summary self-
rating of health (SRH). METHODS: We used data from 4,001 adults from the 2003 
MEPS who had ≥1 of 7 most prevalent chronic conditions and completed the EQ-5D, 
VAS, and SRH. The original 101 VAS categories were collapsed into a 9-category 
item with sufﬁcient responses in each category. Five SRH categories included “excel-
lent”, “very good”, “good”, “fair” and “poor”. The Rasch rating scale and partial 
credit models were used to calibrate the EQ-5D and the single items, respectively. 
Calibrations were conducted using 4 different combinations: EQ-5D alone; EQ-
5D+SRH; EQ-5D+VAS, and EQ-5D+SRH+VAS. Model goodness-of-ﬁt was assessed 
in each disease group using INFIT mean squares (≤1.40). Principal Component Analy-
sis of Rasch Residuals was used to conﬁrm dimensionality examining the proportion 
of total variance explained by Rasch scale, person measures and item measures, 
respectively. RESULTS: Respondents were predominantly white, female, middle aged 
and suffered most commonly from hypertension (32%), diabetes (17%) and depres-
sion (15%). EQ-5D item “anxiety/depression” consistently showed misﬁt to the model 
across 7 conditions when EQ-5D was evaluated alone. The inclusion of VAS and/or 
SRH not only improved model ﬁt, but also increased overall variances explained, and 
improved overall distribution of persons and items along the latent health trait. Speciﬁ-
cally, when both items were included, 4 groups showed good model ﬁt (mean squares 
≤1.40). Consistently across all groups, VAS captured more person measures while 
SRH captured more item measures. CONCLUSIONS: The EQ-5D’s measurement 
qualities are enhanced by the inclusion of VAS/SRH, which captures integral aspect 
of self-valuations on health that are possibly overlooked by the EQ-5D. The EQ-
5D+VAS+SRH may serve as a suitable measurement framework for deriving popula-
tion preference-weights. Consequently, a new valuation algorithm is called for.
PR3
NATIONAL CULTURE AND EQ-5D VALUE SETS
Bailey H1, Kind P2
1The University of the West Indies, Maracas Valley, Trinidad and Tobago, 2University of 
York, York, UK
Background Despite the growing importance of the EQ-5D descriptive system as a 
basis for the valuation of QALYs in cost-utility analysis, for most countries there are 
no EQ-5D social value sets. Researchers and policy makers wishing to use the EQ-5D 
descriptive system in a country for which there is no value set are advised to use one 
from a nearby or ‘similar’ population. Factors other than geographic proximity can 
affect the relative values of EQ-5D states. Objective This study explores the links 
